Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease
- PMID: 17587584
- DOI: 10.1016/j.jocn.2006.06.010
Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease
Abstract
To assess the possible neurological basis of behavioral and psychological symptoms of dementia (BPSD), the relationships between BPSD and cognitive function were evaluated in 40 patients with Alzheimer's disease (AD). BPSD was assessed using the Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW) for behavioral symptoms and psychological symptoms separately, and cognitive function was also assessed using the Cognitive Abilities Screening Instrument (CASI). We found that only behavioral symptoms were associated with cognitive function based on the CASI total score and the score for the CASI attention domain. Administration of risperidone, an atypical anti-psychotic drug, for one month, improved the behavioral symptoms and the scores for the CASI attention and orientation domains. Our data suggest that BPSD in AD may reflect two largely independent pathophysiological processes: one associated with behavioral symptoms partly overlapping with attention, and the other associated with psychological symptoms predominantly unrelated to cognitive function.
Similar articles
-
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.Int J Geriatr Psychiatry. 2007 May;22(5):475-84. doi: 10.1002/gps.1792. Int J Geriatr Psychiatry. 2007. PMID: 17471598
-
Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):205-9. doi: 10.1016/j.pnpbp.2006.09.001. Epub 2006 Oct 3. Prog Neuropsychopharmacol Biol Psychiatry. 2007. PMID: 17020789
-
Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.J Clin Psychiatry. 2001;62 Suppl 21:19-22. J Clin Psychiatry. 2001. PMID: 11584983 Review.
-
Differences in the behavioral and psychological symptoms between Alzheimer's disease and vascular dementia: are the different pharmacologic treatment strategies justifiable?Hum Psychopharmacol. 2003 Apr;18(3):215-20. doi: 10.1002/hup.466. Hum Psychopharmacol. 2003. PMID: 12672174
-
Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.J Clin Psychiatry. 1998;59 Suppl 13:23-30. J Clin Psychiatry. 1998. PMID: 9771827 Review.
Cited by
-
Behavioral and psychological symptoms of dementia and their management.Indian J Psychiatry. 2009 Jan;51 Suppl 1(Suppl1):S77-86. Indian J Psychiatry. 2009. PMID: 21416023 Free PMC article.
-
Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations.Neurology. 2021 Sep 28;97(13):e1276-e1287. doi: 10.1212/WNL.0000000000012598. Epub 2021 Aug 19. Neurology. 2021. PMID: 34413181 Free PMC article.
-
Clinical Significance of Cerebrovascular Biomarkers and White Matter Tract Integrity in Alzheimer Disease: Clinical correlations With Neurobehavioral Data in Cross-Sectional and After 18 Months Follow-ups.Medicine (Baltimore). 2015 Jul;94(28):e1192. doi: 10.1097/MD.0000000000001192. Medicine (Baltimore). 2015. PMID: 26181568 Free PMC article.
-
The Associations Between Neuropsychiatric Symptoms and Cognition in People with Dementia: A Systematic Review and Meta-Analysis.Neuropsychol Rev. 2024 Jun;34(2):581-597. doi: 10.1007/s11065-023-09608-0. Epub 2023 Jul 21. Neuropsychol Rev. 2024. PMID: 37477839 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical